How much revenue does Vivanza Biosciences make?

Vivanza Biosciences reported 74.23 million INR in revenue for fiscal year 2025, down 73.3% from 278.35 million INR in fiscal year 2024. In Q3 2026 revenue was 452.51 million INR.

What companies are similar to Vivanza Biosciences?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Genomic Valley Biotech Limited (GVBL.BO), Adline Chem Lab Ltd (ADLINE.BO), Ganga Pharmaceuticals Limited (GANGAPHARM.BO), Decipher Labs Ltd (DECIPHER.BO).

Vivanza Biosciences Limited (VIVANZA.BO) Stock

About Vivanza Biosciences Limited

Vivanza Biosciences Limited engages in the manufacturing and sale of pharmaceutical products in India. It offers pharmaceuticals in various categories; injectable products, including antifungals, antibiotics, antivirals, and other products for hospital and clinical use; Vivanza medical gloves for medical and surgical use; therapeutic index injection; and veterinary products and feed. The company w...

At a glance

Vivanza Biosciences reported revenue of 74.23 million INR for fiscal year 2025, down 73.3% from fiscal year 2024, and net income of -6.74 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 452.51 million INR, up 2915.7% from a year before.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.